000 02376 a2200661 4500
005 20250517160054.0
264 0 _c20180521
008 201805s 0 0 eng d
022 _a1549-490X
024 7 _a10.1634/theoncologist.2017-0175
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLieu, Christopher H
245 0 0 _aA Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
_h[electronic resource]
260 _bThe oncologist
_c09 2017
300 _a1024-e89 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
650 0 4 _aAcneiform Eruptions
_xepidemiology
650 0 4 _aAdministration, Oral
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xpharmacology
650 0 4 _aAsthenia
_xepidemiology
650 0 4 _aAzetidines
_xpharmacology
650 0 4 _aColorectal Neoplasms
_xdrug therapy
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aDrug Eruptions
_xepidemiology
650 0 4 _aErbB Receptors
_xantagonists & inhibitors
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aHypokalemia
_xepidemiology
650 0 4 _aImmunoglobulin G
_xpharmacology
650 0 4 _aMAP Kinase Kinase 1
_xantagonists & inhibitors
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Staging
650 0 4 _aPiperidines
_xpharmacology
650 0 4 _aProspective Studies
650 0 4 _aProto-Oncogene Proteins p21(ras)
_xgenetics
650 0 4 _aReceptor, ErbB-3
_xantagonists & inhibitors
650 0 4 _aSignal Transduction
_xdrug effects
650 0 4 _aTreatment Outcome
700 1 _aHidalgo, Manuel
700 1 _aBerlin, Jordan D
700 1 _aKo, Andrew H
700 1 _aCervantes, Andres
700 1 _aLoRusso, Patricia
700 1 _aGerber, David E
700 1 _aEder, J Paul
700 1 _aEckhardt, S Gail
700 1 _aKapp, Amy V
700 1 _aTsuhako, Amy
700 1 _aMcCall, Bruce
700 1 _aPirzkall, Andrea
700 1 _aUyei, Anne
700 1 _aTabernero, Josep
773 0 _tThe oncologist
_gvol. 22
_gno. 9
_gp. 1024-e89
856 4 0 _uhttps://doi.org/10.1634/theoncologist.2017-0175
_zAvailable from publisher's website
999 _c27256616
_d27256616